Skip to Main Content
DownloadHi-Res Photo

Francine Foss, MD

Professor of Medicine (Hematology) and of Dermatology; Director, Multidisciplinary T cell Lymphoma Program, Hematology; Scientific Leader, Lymphoma DART, Yale Cancer Center; Host, Yale Cancer Center Answers, Yale Cancer Center

Contact Information

Francine Foss, MD

Mailing Address

  • Hematology

    PO Box 208028, 333 Cedar Street, TMP 3

    New Haven, CT 06520-8028

    United States

Download CV

Related Links

Yale Medicine

Patient Care

Are you a patient?Please visit the Yale Medicine website for information about the services we offer and making an appointment.View Doctor Profile

Extensive Research Description

Over the last 10 years I have been a leader in the establishment of an international T cell lymphoma working group. I initiated a T Cell Lymphoma workshop at the International Conference on Malignant Lymphoma 12 years ago and from that workshop, the United States Peripheral T cell Lymphoma group was formed. I subsequently initiated the first T Cell Lymphoma Forum, an international meeting incorporating basic and clinical sciences related to T cell lymphomas. (www.tcellforum.com). This meeting is now recognized as the pre-eminent international T cell Lymphoma meeting. A number of collaborations have arisen from these meetings and there is now a world-wide effort to coordinate the care of patients with T cell lymphomas.

Another initiative that I undertook was to establish a T Cell Lymphoma Registry. I initiated and am the Principal Investigator for the COMPLETE T cell Registry (www. Clinical trials.gov/COMPLETE REGISTRY). This is a US based registry to determine the frequency of types of T cell lymphoma, physician’s treatment patterns, outcomes with therapy, and prognostic factors associated with common and rare subtypes. Thus far this registry has enrolled 500 patients in its first phase, and the second phase of enrollment is about to begin. I have also been a co-Founder of a European based registry, the TCELL PROJECT (www.TCELLPROJECT.org). This registry is similar to COMPLETE but includes pathologic review and includes many other countries in Asia, South America, and Europe as well as in the US. This registry has enrolled 1000 patients and is ongoing. In a recent initiative, I have collaborated with several countries in Latin American to initiate their own registry which will interface with our existing registries.

I was one of the founders of the United States Cutaneous Lymphoma Consortium. This organization includes oncologists, dermatologists, radiation oncologists, and pathologists and its goal is to develop novel clinical trials and to define clinical approaches for patients with cutaneous lymphomas. I also serve as a Co-Chair of the Registry Committee and have been instrumental in starting a patient registry for both T and B cell cutaneous lymphoma patients. This registry has a research focus. I am now the President of the USCLC.

Coauthors

Research Interests

Biological Factors; Graft vs Host Disease; Hodgkin Disease; Immune System Diseases; Leukemia, Hairy Cell; Leukemia, Lymphoid; Lymphoma, Non-Hodgkin; Lymphoproliferative Disorders; Sezary Syndrome; Skin Neoplasms; Leukemia, B-Cell; Leukemia, T-Cell; Leukemia, Prolymphocytic, T-Cell; Leukemia, Prolymphocytic, B-Cell; Composite Lymphoma; Chemicals and Drugs

Public Health Interests

Immunology

Selected Publications

  • Uncovering the Potential of Phosphatidylinositol 3-Kinase Inhibitors in Cutaneous T-Cell Lymphoma: Insights from High-Throughput In Vitro Screenings.King ALO, Mirza FN, Lewis JM, Umlauf S, Surovtseva Y, Carlson KR, Foss FM, Girardi M. Uncovering the Potential of Phosphatidylinositol 3-Kinase Inhibitors in Cutaneous T-Cell Lymphoma: Insights from High-Throughput In Vitro Screenings. The Journal Of Investigative Dermatology 2022, 142: 254-257. PMID: 34293349, DOI: 10.1016/j.jid.2021.04.035.
  • Screening Novel Agent Combinations to Expedite CTCL Therapeutic Development.Mirza FN, Yumeen S, Lewis JM, King ALO, Kim SR, Carlson KR, Umlauf S, Surovtseva YV, Foss FM, Girardi M. Screening Novel Agent Combinations to Expedite CTCL Therapeutic Development. The Journal Of Investigative Dermatology 2021, 141: 217-221. PMID: 32534802, DOI: 10.1016/j.jid.2020.05.097.
  • B-cell lymphoma 2 inhibitor venetoclax treatment of a patient with cutaneous T-cell lymphoma.King ALO, Mirza FN, Lewis JM, Carlson KR, Huntington S, Foss FM, Girardi M. B-cell lymphoma 2 inhibitor venetoclax treatment of a patient with cutaneous T-cell lymphoma. JAAD Case Reports 2021, 8: 89-92. PMID: 33537387, PMCID: PMC7838714, DOI: 10.1016/j.jdcr.2020.12.025.
  • New nonchemotherapy treatment options for cutaneous T-cell lymphomas.Xu S, Foss F. New nonchemotherapy treatment options for cutaneous T-cell lymphomas. Expert Review Of Anticancer Therapy 2021, 21: 1017-1028. PMID: 33554707, DOI: 10.1080/14737140.2021.1882859.
  • Belinostat in combination with standard cyclophosphamide, doxorubicin, vincristine and prednisone as first-line treatment for patients with newly diagnosed peripheral T-cell lymphoma.Johnston PB, Cashen AF, Nikolinakos PG, Beaven AW, Barta SK, Bhat G, Hasal SJ, De Vos S, Oki Y, Deng C, Foss FM. Belinostat in combination with standard cyclophosphamide, doxorubicin, vincristine and prednisone as first-line treatment for patients with newly diagnosed peripheral T-cell lymphoma. Experimental Hematology & Oncology 2021, 10: 15. PMID: 33602316, PMCID: PMC7893947, DOI: 10.1186/s40164-021-00203-8.
  • Mitigating the risk of COVID-19 exposure by transitioning from clinic-based to home-based immune globulin infusion.Perreault S, Schiffer M, Clinchy-Jarmoszko V, Bocchetta N, Barbarotta L, Abdelghany O, Foss F, Huntington S, Seropian S, Isufi I. Mitigating the risk of COVID-19 exposure by transitioning from clinic-based to home-based immune globulin infusion. American Journal Of Health-system Pharmacy : AJHP : Official Journal Of The American Society Of Health-System Pharmacists 2021, 78: 1112-1117. PMID: 33617630, PMCID: PMC7929449, DOI: 10.1093/ajhp/zxab072.
  • Necrotic papulonodules on the legs.Zhou A, Damsky W, Girardi M, Foss FM, Vesely MD. Necrotic papulonodules on the legs. JAAD Case Reports 2021, 11: 10-12. PMID: 33898676, PMCID: PMC8056172, DOI: 10.1016/j.jdcr.2021.03.012.
  • How we treat advanced stage cutaneous T-cell lymphoma - mycosis fungoides and Sézary syndrome.Sethi TK, Montanari F, Foss F, Reddy N. How we treat advanced stage cutaneous T-cell lymphoma - mycosis fungoides and Sézary syndrome. British Journal Of Haematology 2021, 195: 352-364. PMID: 33987825, DOI: 10.1111/bjh.17458.
  • Mogamulizumab-Associated Acute Myocarditis in a Patient With T-Cell Lymphoma.Kwan JM, Odanovic N, Arbune A, Higgins A, Henry M, Greif D, Foss F, Baldassarre LA. Mogamulizumab-Associated Acute Myocarditis in a Patient With T-Cell Lymphoma. JACC. Case Reports 2021, 3: 1018-1023. PMID: 34317676, PMCID: PMC8311348, DOI: 10.1016/j.jaccas.2021.04.001.
  • Primary Cutaneous Lymphoma: Recommendations for Clinical Trial Design and Staging Update from the ISCL, USCLC, and EORTC.Olsen EA, Whittaker S, Willemze R, Pinter-Brown L, Foss FM, Geskin LJ, Schwartz LH, Horwitz SM, Guitart J, Zic J, Kim YH, Wood GS, Duvic M, Ai WZ, Girardi M, Gru A, Guenova E, Hodak E, Hoppe RT, Kempf W, Kim EJ, Lechowicz MJ, Ortiz-Romero PL, Papadavid E, Quaglino P, Pittelkow MR, Prince HM, Sanches JA, Sugaya M, Vermeer MH, Zain J, Knobler R, Stadler R, Bagot M, Scarisbrick JJ. Primary Cutaneous Lymphoma: Recommendations for Clinical Trial Design and Staging Update from the ISCL, USCLC, and EORTC. Blood 2021 PMID: 34758074, DOI: 10.1182/blood.2021012057.
  • Outcomes for Relapsed and Refractory Peripheral T-Cell Lymphoma Patients after Front-Line Therapy from the COMPLETE Registry.Lansigan F, Horwitz SM, Pinter-Brown LC, Rosen ST, Pro B, Hsi ED, Federico M, Gisselbrecht C, Schwartz M, Bellm LA, Acosta M, Shustov AR, Advani RH, Feldman T, Lechowicz MJ, Smith SM, Tulpule A, Craig MD, Greer JP, Kahl BS, Leach JW, Morganstein N, Casulo C, Park SI, Foss FM. Outcomes for Relapsed and Refractory Peripheral T-Cell Lymphoma Patients after Front-Line Therapy from the COMPLETE Registry. Acta Haematologica 2020, 143: 40-50. PMID: 31315113, DOI: 10.1159/000500666.
  • Pembrolizumab in Relapsed and Refractory Mycosis Fungoides and Sézary Syndrome: A Multicenter Phase II Study.Khodadoust MS, Rook AH, Porcu P, Foss F, Moskowitz AJ, Shustov A, Shanbhag S, Sokol L, Fling SP, Ramchurren N, Pierce R, Davis A, Shine R, Li S, Fong S, Kim J, Yang Y, Blumenschein WM, Yearley JH, Das B, Patidar R, Datta V, Cantu E, McCutcheon JN, Karlovich C, Williams PM, Subrahmanyam PB, Maecker HT, Horwitz SM, Sharon E, Kohrt HE, Cheever MA, Kim YH. Pembrolizumab in Relapsed and Refractory Mycosis Fungoides and Sézary Syndrome: A Multicenter Phase II Study. Journal Of Clinical Oncology : Official Journal Of The American Society Of Clinical Oncology 2020, 38: 20-28. PMID: 31532724, PMCID: PMC6943974, DOI: 10.1200/JCO.19.01056.
  • Incidence and outcomes of rare T cell lymphomas from the T Cell Project: hepatosplenic, enteropathy associated and peripheral gamma delta T cell lymphomas.Foss FM, Horwitz SM, Civallero M, Bellei M, Marcheselli L, Kim WS, Cabrera ME, Dlouhy I, Nagler A, Advani RH, Pesce EA, Ko YH, Montoto S, Chiattone C, Moskowitz A, Spina M, Cesaretti M, Biasoli I, Federico M. Incidence and outcomes of rare T cell lymphomas from the T Cell Project: hepatosplenic, enteropathy associated and peripheral gamma delta T cell lymphomas. American Journal Of Hematology 2020, 95: 151-155. PMID: 31709579, PMCID: PMC8025136, DOI: 10.1002/ajh.25674.
  • United States Cutaneous Lymphoma Consortium recommendations for treatment of cutaneous lymphomas during the COVID-19 pandemic.Zic JA, Ai W, Akilov OE, Carter JB, Duvic M, Foss F, Girardi M, Gru AA, Kim E, Musiek A, Olsen EA, Schieke SM, Shinohara M, Zain JM, Geskin LJ. United States Cutaneous Lymphoma Consortium recommendations for treatment of cutaneous lymphomas during the COVID-19 pandemic. Journal Of The American Academy Of Dermatology 2020, 83: 703-704. PMID: 32305443, PMCID: PMC7161526, DOI: 10.1016/j.jaad.2020.04.049.
  • JAK inhibition synergistically potentiates BCL2, BET, HDAC, and proteasome inhibition in advanced CTCL.Yumeen S, Mirza FN, Lewis JM, King ALO, Kim SR, Carlson KR, Umlauf SR, Surovtseva YV, Foss FM, Girardi M. JAK inhibition synergistically potentiates BCL2, BET, HDAC, and proteasome inhibition in advanced CTCL. Blood Advances 2020, 4: 2213-2226. PMID: 32437546, PMCID: PMC7252559, DOI: 10.1182/bloodadvances.2020001756.
  • Outcomes of Patients with Transformed Mycosis Fungoides: Analysis from a Prospective Multicenter US Cohort Study.Lansigan F, Horwitz SM, Pinter-Brown LC, Carson KR, Shustov AR, Rosen ST, Pro B, Hsi ED, Federico M, Gisselbrecht C, Schwartz M, Bellm LA, Acosta M, Foss FM. Outcomes of Patients with Transformed Mycosis Fungoides: Analysis from a Prospective Multicenter US Cohort Study. Clinical Lymphoma, Myeloma & Leukemia 2020, 20: 744-748. PMID: 32532611, PMCID: PMC8447249, DOI: 10.1016/j.clml.2020.05.001.
  • Outcomes for allogeneic stem cell transplantation in refractory mycosis fungoides and primary cutaneous gamma Delta T cell lymphomas.Isufi I, Seropian S, Gowda L, Wilson LD, Roberts K, Girardi M, Perreault S, Foss F. Outcomes for allogeneic stem cell transplantation in refractory mycosis fungoides and primary cutaneous gamma Delta T cell lymphomas. Leukemia & Lymphoma 2020, 61: 2955-2961. PMID: 32643494, DOI: 10.1080/10428194.2020.1790555.
  • Attenuated Novel SARS Coronavirus 2 Infection in an Allogeneic Hematopoietic Stem Cell Transplant Patient on Ruxolitinib.Foss FM, Rubinowitz A, Landry ML, Isufi I, Gowda L, Seropian S, Perreault S, Shenoi SV. Attenuated Novel SARS Coronavirus 2 Infection in an Allogeneic Hematopoietic Stem Cell Transplant Patient on Ruxolitinib. Clinical Lymphoma, Myeloma & Leukemia 2020, 20: 720-723. PMID: 32727701, PMCID: PMC7316063, DOI: 10.1016/j.clml.2020.06.014.
  • Incorporation of extracorporeal photopheresis into a reduced intensity conditioning regimen in myelodysplastic syndrome and aggressive lymphoma: results from ECOG 1402 and 1902.Foss FM, Wang XV, Luger SM, Jegede O, Miller KB, Stadtmauer EA, Whiteside TL, Avigan DE, Gascoyne RD, Arber D, Wagner H, Strair RK, Hogan WJ, Sprague KA, Lazarus HM, Litzow MR, Tallman MS, Horning SJ. Incorporation of extracorporeal photopheresis into a reduced intensity conditioning regimen in myelodysplastic syndrome and aggressive lymphoma: results from ECOG 1402 and 1902. Transfusion 2020, 60: 1867-1872. PMID: 32654201, PMCID: PMC7606221, DOI: 10.1111/trf.15798.
  • Cost-effectiveness of polatuzumab vedotin in relapsed or refractory diffuse large B-cell lymphoma.Patel KK, Isufi I, Kothari S, Foss F, Huntington S. Cost-effectiveness of polatuzumab vedotin in relapsed or refractory diffuse large B-cell lymphoma. Leukemia & Lymphoma 2020, 61: 3387-3394. PMID: 32835553, DOI: 10.1080/10428194.2020.1808208.
  • Interleukin-17 blockade downregulates NOD2 in skin and may promote paradoxical sarcoidosis.Wang A, Hornick N, Lim Y, Gehlhausen J, Siegel J, Wang J, Foss F, Lim I, Zubek A, Milstone L, Galan A, King B, Damsky W. Interleukin-17 blockade downregulates NOD2 in skin and may promote paradoxical sarcoidosis. Journal Of The European Academy Of Dermatology And Venereology : JEADV 2020, 34: e497-e499. PMID: 32249470, DOI: 10.1111/jdv.16416.
  • Development or worsening of sarcoidosis associated with IL-17 blockade for psoriasis.Hornick N, Wang A, Lim Y, Gehlhausen J, Siegel J, Wang J, Foss F, Lim I, Zubek A, Milstone L, Galan A, King B, Damsky W. Development or worsening of sarcoidosis associated with IL-17 blockade for psoriasis. Journal Of The European Academy Of Dermatology And Venereology : JEADV 2020, 34: e583-e585. PMID: 32277505, DOI: 10.1111/jdv.16451.
  • Long-term follow-up of a single institution pilot study of sirolimus, tacrolimus, and short course methotrexate for graft versus host disease prophylaxis in mismatched unrelated donor allogeneic stem cell transplantation.Kim TK, DeVeaux M, Stahl M, Perreault S, Isufi I, Cooper D, Foss F, Shlomchik W, Zelterman D, Zeidan AM, Seropian S. Long-term follow-up of a single institution pilot study of sirolimus, tacrolimus, and short course methotrexate for graft versus host disease prophylaxis in mismatched unrelated donor allogeneic stem cell transplantation. Annals Of Hematology 2019, 98: 237-240. PMID: 30027436, DOI: 10.1007/s00277-018-3427-1.
  • Cutaneous T-Cell Lymphoma: Trends in Radiation Doses and Patterns of Care 2004-2015.Miccio JA, Wilson LD, Kann BH, Jairam V, Beckta J, Foss FM, Yeboa DN. Cutaneous T-Cell Lymphoma: Trends in Radiation Doses and Patterns of Care 2004-2015. Anticancer Research 2019, 39: 253-259. PMID: 30591466, DOI: 10.21873/anticanres.13105.
  • Hepatosplenic T-Cell Lymphomas.Gowda L, Foss F. Hepatosplenic T-Cell Lymphomas. Cancer Treatment And Research 2019, 176: 185-193. PMID: 30596219, DOI: 10.1007/978-3-319-99716-2_9.
  • The role of autologous stem cell transplantation in patients with nodal peripheral T-cell lymphomas in first complete remission: Report from COMPLETE, a prospective, multicenter cohort study.Park SI, Horwitz SM, Foss FM, Pinter-Brown LC, Carson KR, Rosen ST, Pro B, Hsi ED, Federico M, Gisselbrecht C, Schwartz M, Bellm LA, Acosta M, Advani RH, Feldman T, Lechowicz MJ, Smith SM, Lansigan F, Tulpule A, Craig MD, Greer JP, Kahl BS, Leach JW, Morganstein N, Casulo C, Shustov AR. The role of autologous stem cell transplantation in patients with nodal peripheral T-cell lymphomas in first complete remission: Report from COMPLETE, a prospective, multicenter cohort study. Cancer 2019, 125: 1507-1517. PMID: 30694529, PMCID: PMC8269282, DOI: 10.1002/cncr.31861.
  • The impact of a multimodal approach to vancomycin discontinuation in hematopoietic stem cell transplant recipients (HSCT) with febrile neutropenia (FN).Perreault S, McManus D, Bar N, Foss F, Gowda L, Isufi I, Seropian S, Malinis M, Topal JE. The impact of a multimodal approach to vancomycin discontinuation in hematopoietic stem cell transplant recipients (HSCT) with febrile neutropenia (FN). Transplant Infectious Disease : An Official Journal Of The Transplantation Society 2019, 21: e13059. PMID: 30737868, DOI: 10.1111/tid.13059.
  • Randomized Phase III Study of Alisertib or Investigator's Choice (Selected Single Agent) in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma.O'Connor OA, Özcan M, Jacobsen ED, Roncero JM, Trotman J, Demeter J, Masszi T, Pereira J, Ramchandren R, Beaven A, Caballero D, Horwitz SM, Lennard A, Turgut M, Hamerschlak N, d'Amore FA, Foss F, Kim WS, Leonard JP, Zinzani PL, Chiattone CS, Hsi ED, Trümper L, Liu H, Sheldon-Waniga E, Ullmann CD, Venkatakrishnan K, Leonard EJ, Shustov AR. Randomized Phase III Study of Alisertib or Investigator's Choice (Selected Single Agent) in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma. Journal Of Clinical Oncology : Official Journal Of The American Society Of Clinical Oncology 2019, 37: 613-623. PMID: 30707661, PMCID: PMC6494247, DOI: 10.1200/JCO.18.00899.
  • Single agents vs combination chemotherapy in relapsed and refractory peripheral T-cell lymphoma: Results from the comprehensive oncology measures for peripheral T-cell lymphoma treatment (COMPLETE) registry.Stuver RN, Khan N, Schwartz M, Acosta M, Federico M, Gisselbrecht C, Horwitz SM, Lansigan F, Pinter-Brown LC, Pro B, Shustov AR, Foss FM, Jain S. Single agents vs combination chemotherapy in relapsed and refractory peripheral T-cell lymphoma: Results from the comprehensive oncology measures for peripheral T-cell lymphoma treatment (COMPLETE) registry. American Journal Of Hematology 2019, 94: 641-649. PMID: 30896890, PMCID: PMC7928240, DOI: 10.1002/ajh.25463.
  • Effect of leucovorin administration on mucositis and skin reactions in patients with peripheral T-cell lymphoma or cutaneous T-cell lymphoma treated with pralatrexate.Foss FM, Parker TL, Girardi M, Li A. Effect of leucovorin administration on mucositis and skin reactions in patients with peripheral T-cell lymphoma or cutaneous T-cell lymphoma treated with pralatrexate. Leukemia & Lymphoma 2019, 60: 2927-2930. PMID: 31119966, DOI: 10.1080/10428194.2019.1612061.
  • A drug safety evaluation of mogamulizumab for the treatment of cutaneous T-Cell lymphoma.Afifi S, Mohamed S, Zhao J, Foss F. A drug safety evaluation of mogamulizumab for the treatment of cutaneous T-Cell lymphoma. Expert Opinion On Drug Safety 2019, 18: 769-776. PMID: 31303060, DOI: 10.1080/14740338.2019.1643837.
  • DUSP22-IRF4 rearrangement in AIDS-associated ALK-negative anaplastic large cell lymphoma.Wang M, Kibbi N, Ring N, Siddon A, Foss F, Totonchy M. DUSP22-IRF4 rearrangement in AIDS-associated ALK-negative anaplastic large cell lymphoma. BMJ Case Reports 2019, 12 PMID: 31570354, PMCID: PMC6768350, DOI: 10.1136/bcr-2019-230641.
  • Activity of the PI3K-δ,γ inhibitor duvelisib in a phase 1 trial and preclinical models of T-cell lymphoma.Horwitz SM, Koch R, Porcu P, Oki Y, Moskowitz A, Perez M, Myskowski P, Officer A, Jaffe JD, Morrow SN, Allen K, Douglas M, Stern H, Sweeney J, Kelly P, Kelly V, Aster JC, Weaver D, Foss FM, Weinstock DM. Activity of the PI3K-δ,γ inhibitor duvelisib in a phase 1 trial and preclinical models of T-cell lymphoma. Blood 2018, 131: 888-898. PMID: 29233821, PMCID: PMC5824337, DOI: 10.1182/blood-2017-08-802470.
  • Duvelisib, a novel oral dual inhibitor of PI3K-δ,γ, is clinically active in advanced hematologic malignancies.Flinn IW, O'Brien S, Kahl B, Patel M, Oki Y, Foss FF, Porcu P, Jones J, Burger JA, Jain N, Kelly VM, Allen K, Douglas M, Sweeney J, Kelly P, Horwitz S. Duvelisib, a novel oral dual inhibitor of PI3K-δ,γ, is clinically active in advanced hematologic malignancies. Blood 2018, 131: 877-887. PMID: 29191916, PMCID: PMC6033052, DOI: 10.1182/blood-2017-05-786566.
  • Transplantation in the Treatment of Primary Cutaneous Aggressive Epidermotropic Cytotoxic CD8-Positive T-Cell Lymphoma.Cyrenne BM, Gibson JF, Subtil A, Girardi M, Isufi I, Seropian S, Foss F. Transplantation in the Treatment of Primary Cutaneous Aggressive Epidermotropic Cytotoxic CD8-Positive T-Cell Lymphoma. Clinical Lymphoma, Myeloma & Leukemia 2018, 18: e85-e93. PMID: 29223388, DOI: 10.1016/j.clml.2017.11.004.
  • A Phase I Dose-Escalation Study of Clofarabine in Patients with Relapsed or Refractory Low-Grade or Intermediate-Grade B-Cell or T-Cell Lymphoma.Foss FM, Parker T. A Phase I Dose-Escalation Study of Clofarabine in Patients with Relapsed or Refractory Low-Grade or Intermediate-Grade B-Cell or T-Cell Lymphoma. The Oncologist 2018, 23: 397-e30. PMID: 29438091, PMCID: PMC5896711, DOI: 10.1634/theoncologist.2017-0658.
  • The outcome of peripheral T-cell lymphoma patients failing first-line therapy: a report from the prospective, International T-Cell Project.Bellei M, Foss FM, Shustov AR, Horwitz SM, Marcheselli L, Kim WS, Cabrera ME, Dlouhy I, Nagler A, Advani RH, Pesce EA, Ko YH, Martinez V, Montoto S, Chiattone C, Moskowitz A, Spina M, Biasoli I, Manni M, Federico M. The outcome of peripheral T-cell lymphoma patients failing first-line therapy: a report from the prospective, International T-Cell Project. Haematologica 2018, 103: 1191-1197. PMID: 29599200, PMCID: PMC6029527, DOI: 10.3324/haematol.2017.186577.
  • Peripheral T cell lymphoma, not otherwise specified (PTCL-NOS). A new prognostic model developed by the International T cell Project Network.Federico M, Bellei M, Marcheselli L, Schwartz M, Manni M, Tarantino V, Pileri S, Ko YH, Cabrera ME, Horwitz S, Kim WS, Shustov A, Foss FM, Nagler A, Carson K, Pinter-Brown LC, Montoto S, Spina M, Feldman TA, Lechowicz MJ, Smith SM, Lansigan F, Gabus R, Vose JM, Advani RH. Peripheral T cell lymphoma, not otherwise specified (PTCL-NOS). A new prognostic model developed by the International T cell Project Network. British Journal Of Haematology 2018, 181: 760-769. PMID: 29672827, PMCID: PMC6033106, DOI: 10.1111/bjh.15258.
  • BET inhibition in advanced cutaneous T cell lymphoma is synergistically potentiated by BCL2 inhibition or HDAC inhibition.Kim SR, Lewis JM, Cyrenne BM, Monico PF, Mirza FN, Carlson KR, Foss FM, Girardi M. BET inhibition in advanced cutaneous T cell lymphoma is synergistically potentiated by BCL2 inhibition or HDAC inhibition. Oncotarget 2018, 9: 29193-29207. PMID: 30018745, PMCID: PMC6044378, DOI: 10.18632/oncotarget.25670.
  • Duvelisib, an oral dual PI3K-δ, γ inhibitor, shows clinical activity in indolent non-Hodgkin lymphoma in a phase 1 study.Flinn IW, Patel M, Oki Y, Horwitz S, Foss FF, Allen K, Douglas M, Stern H, Sweeney J, Kharidia J, Kelly P, Kelly VM, Kahl B. Duvelisib, an oral dual PI3K-δ, γ inhibitor, shows clinical activity in indolent non-Hodgkin lymphoma in a phase 1 study. American Journal Of Hematology 2018, 93: 1311-1317. PMID: 30033575, PMCID: PMC6220789, DOI: 10.1002/ajh.25228.
  • Duvelisib, an oral dual PI3K-δ,γ inhibitor, shows clinical and pharmacodynamic activity in chronic lymphocytic leukemia and small lymphocytic lymphoma in a phase 1 study.O'Brien S, Patel M, Kahl BS, Horwitz SM, Foss FM, Porcu P, Jones J, Burger J, Jain N, Allen K, Faia K, Douglas M, Stern HM, Sweeney J, Kelly P, Kelly V, Flinn I. Duvelisib, an oral dual PI3K-δ,γ inhibitor, shows clinical and pharmacodynamic activity in chronic lymphocytic leukemia and small lymphocytic lymphoma in a phase 1 study. American Journal Of Hematology 2018, 93: 1318-1326. PMID: 30094870, PMCID: PMC8260004, DOI: 10.1002/ajh.25243.
  • Clinical Activity of Pralatrexate in Patients With Cutaneous T-Cell Lymphoma Treated With Varying Doses of Pralatrexate.Foss FM, Parker TL, Girardi M, Li A. Clinical Activity of Pralatrexate in Patients With Cutaneous T-Cell Lymphoma Treated With Varying Doses of Pralatrexate. Clinical Lymphoma, Myeloma & Leukemia 2018, 18: e445-e447. PMID: 30181105, DOI: 10.1016/j.clml.2018.06.020.
  • Revised Dose Ramp-Up to Mitigate the Risk of Tumor Lysis Syndrome When Initiating Venetoclax in Patients With Mantle Cell Lymphoma.Davids MS, von Keudell G, Portell CA, Cohen JB, Fisher DC, Foss F, Roberts AW, Seymour JF, Humerickhouse RA, Tam CS. Revised Dose Ramp-Up to Mitigate the Risk of Tumor Lysis Syndrome When Initiating Venetoclax in Patients With Mantle Cell Lymphoma. Journal Of Clinical Oncology : Official Journal Of The American Society Of Clinical Oncology 2018, JCO1800359. PMID: 30359156, DOI: 10.1200/JCO.18.00359.
  • Neurolymphomatosis of the thoracic sympathetic chain.Kaulen LD, Foss FM, Fulbright RK, Huttner A, Baehring JM. Neurolymphomatosis of the thoracic sympathetic chain. Neurology 2017, 89: 1926-1927. PMID: 28939669, PMCID: PMC5664295, DOI: 10.1212/WNL.0000000000004600.
  • Analysis of Peripheral T-cell Lymphoma Diagnostic Workup in the United States.Hsi ED, Horwitz SM, Carson KR, Pinter-Brown LC, Rosen ST, Pro B, Federico M, Gisselbrecht C, Schwartz M, Bellm LA, Acosta M, Collie AM, Gruver AM, Grzywacz BJ, Turakhia S, Shustov AR, Advani RH, Feldman T, Lechowicz MJ, Smith SM, Lansigan F, Tulpule A, Craig MD, Greer JP, Kahl BS, Leach JW, Morganstein N, Casulo C, Park SI, Foss FM. Analysis of Peripheral T-cell Lymphoma Diagnostic Workup in the United States. Clinical Lymphoma, Myeloma & Leukemia 2017, 17: 193-200. PMID: 28209473, DOI: 10.1016/j.clml.2016.10.001.
  • Infusion reactions are common after high-dose carmustine in BEAM chemotherapy and are not reduced by lengthening the time of administration.Perreault S, Baker J, Medoff E, Pratt K, Foss F, Isufi I, Seropian S, Cooper DL. Infusion reactions are common after high-dose carmustine in BEAM chemotherapy and are not reduced by lengthening the time of administration. Supportive Care In Cancer : Official Journal Of The Multinational Association Of Supportive Care In Cancer 2017, 25: 205-208. PMID: 27614867, DOI: 10.1007/s00520-016-3399-4.
  • Synergy of BCL2 and histone deacetylase inhibition against leukemic cells from cutaneous T-cell lymphoma patients.Cyrenne BM, Lewis JM, Weed JG, Carlson KR, Mirza FN, Foss FM, Girardi M. Synergy of BCL2 and histone deacetylase inhibition against leukemic cells from cutaneous T-cell lymphoma patients. Blood 2017, 130: 2073-2083. PMID: 28972015, PMCID: PMC5680613, DOI: 10.1182/blood-2017-06-792150.
  • Clinical Practice Recommendations on Indication and Timing of Hematopoietic Cell Transplantation in Mature T Cell and NK/T Cell Lymphomas: An International Collaborative Effort on Behalf of the Guidelines Committee of the American Society for Blood and Marrow Transplantation.Kharfan-Dabaja MA, Kumar A, Ayala E, Hamadani M, Reimer P, Gisselbrecht C, d'Amore F, Jantunen E, Ishida T, Bazarbachi A, Foss F, Advani R, Fenske TS, Lazarus HM, Friedberg JW, Aljurf M, Sokol L, Tobinai K, Tse E, Burns LJ, Chavez JC, Reddy NM, Suzuki R, Ahmed S, Nademanee A, Mohty M, Gopal AK, Fanale MA, Pro B, Moskowitz AJ, Sureda A, Perales MA, Carpenter PA, Savani BN. Clinical Practice Recommendations on Indication and Timing of Hematopoietic Cell Transplantation in Mature T Cell and NK/T Cell Lymphomas: An International Collaborative Effort on Behalf of the Guidelines Committee of the American Society for Blood and Marrow Transplantation. Biology Of Blood And Marrow Transplantation : Journal Of The American Society For Blood And Marrow Transplantation 2017, 23: 1826-1838. PMID: 28797780, DOI: 10.1016/j.bbmt.2017.07.027.
  • FISH Panel for Leukemic CTCL.Weed J, Gibson J, Lewis J, Carlson K, Foss F, Choi J, Li P, Girardi M. FISH Panel for Leukemic CTCL. The Journal Of Investigative Dermatology 2017, 137: 751-753. PMID: 27836797, PMCID: PMC5419071, DOI: 10.1016/j.jid.2016.10.037.
  • Responses to romidepsin by line of therapy in patients with relapsed or refractory peripheral T-cell lymphoma.Foss F, Pro B, Miles Prince H, Sokol L, Caballero D, Horwitz S, Coiffier B. Responses to romidepsin by line of therapy in patients with relapsed or refractory peripheral T-cell lymphoma. Cancer Medicine 2017, 6: 36-44. PMID: 27981793, PMCID: PMC5269566, DOI: 10.1002/cam4.939.
  • A prospective cohort study of patients with peripheral T-cell lymphoma in the United States.Horwitz SM, Pinter-Brown LC, Rosen ST, Pro B, Hsi ED, Federico M, Gisselbrecht C, Schwartz M, Bellm LA, Acosta MA, Shustov AR, Advani RH, Feldman TA, Lechowicz MJ, Smith SM, Lansigan F, Tulpule A, Craig MD, Greer JP, Kahl BS, Leach JW, Morganstein N, Casulo C, Park SI, Foss FM. A prospective cohort study of patients with peripheral T-cell lymphoma in the United States. Cancer 2017, 123: 1174-1183. PMID: 27911989, PMCID: PMC5650190, DOI: 10.1002/cncr.30416.
  • Annual Facility Treatment Volume and Patient Survival for Mycosis Fungoides and Sézary Syndrome.Kann BH, Park HS, Yeboa DN, Aneja S, Girardi M, Foss FM, Roberts KB, Wilson LD. Annual Facility Treatment Volume and Patient Survival for Mycosis Fungoides and Sézary Syndrome. Clinical Lymphoma, Myeloma & Leukemia 2017, 17: 520-526.e2. PMID: 28655598, DOI: 10.1016/j.clml.2017.05.017.
  • Erratum to: Romidepsin for the treatment of relapsed/refractory peripheral T cell lymphoma: prolonged stable disease provides clinical benefits for patients in the pivotal trial.Foss F, Horwitz S, Pro B, Miles Prince H, Sokol L, Balser B, Wolfson J, Coiffier B. Erratum to: Romidepsin for the treatment of relapsed/refractory peripheral T cell lymphoma: prolonged stable disease provides clinical benefits for patients in the pivotal trial. Journal Of Hematology & Oncology 2017, 10: 154. PMID: 28923081, PMCID: PMC5603163, DOI: 10.1186/s13045-017-0518-8.
  • Romidepsin induces durable responses in patients with relapsed or refractory angioimmunoblastic T-cell lymphoma.Pro B, Horwitz SM, Prince HM, Foss FM, Sokol L, Greenwood M, Caballero D, Morschhauser F, Wilhelm M, Iyer SP, Shustov AR, Wolfson J, Balser BE, Coiffier B. Romidepsin induces durable responses in patients with relapsed or refractory angioimmunoblastic T-cell lymphoma. Hematological Oncology 2017, 35: 914-917. PMID: 27402335, PMCID: PMC5763404, DOI: 10.1002/hon.2320.
  • Primary cutaneous aggressive epidermotropic cytotoxic CD8+ T-cell lymphoma: long-term remission after brentuximab vedotin.Cyrenne BM, Subtil A, Girardi M, Foss F. Primary cutaneous aggressive epidermotropic cytotoxic CD8+ T-cell lymphoma: long-term remission after brentuximab vedotin. International Journal Of Dermatology 2017, 56: 1448-1450. PMID: 29047111, DOI: 10.1111/ijd.13792.
  • Mycosis Fungoides and Sezary Syndrome.Foss FM, Girardi M. Mycosis Fungoides and Sezary Syndrome. Hematology/oncology Clinics Of North America 2017, 31: 297-315. PMID: 28340880, DOI: 10.1016/j.hoc.2016.11.008.
  • Autologous Stem Cell Mobilization in the Age of Plerixafor.Cooper DL, Medoff E, Patel N, Baker J, Pratt K, Foss F, Seropian SE, Perreault S, Wu Y. Autologous Stem Cell Mobilization in the Age of Plerixafor. Clinical Lymphoma, Myeloma & Leukemia 2016, 16: 411-6. PMID: 27245311, DOI: 10.1016/j.clml.2016.04.007.
  • Romidepsin for the treatment of relapsed/refractory peripheral T cell lymphoma: prolonged stable disease provides clinical benefits for patients in the pivotal trial.Foss F, Horwitz S, Pro B, Prince HM, Sokol L, Balser B, Wolfson J, Coiffier B. Romidepsin for the treatment of relapsed/refractory peripheral T cell lymphoma: prolonged stable disease provides clinical benefits for patients in the pivotal trial. Journal Of Hematology & Oncology 2016, 9: 22. PMID: 26965915, PMCID: PMC4785666, DOI: 10.1186/s13045-016-0243-8.
  • Cutaneous T-cell lymphoma (CTCL): Current practices in blood assessment and the utility of T-cell receptor (TCR)-Vβ chain restriction.Gibson JF, Huang J, Liu KJ, Carlson KR, Foss F, Choi J, Edelson R, Hussong JW, Mohl R, Hill S, Girardi M. Cutaneous T-cell lymphoma (CTCL): Current practices in blood assessment and the utility of T-cell receptor (TCR)-Vβ chain restriction. Journal Of The American Academy Of Dermatology 2016, 74: 870-7. PMID: 26874819, PMCID: PMC4835257, DOI: 10.1016/j.jaad.2015.12.018.
  • Clinical Efficacy of Romidepsin in Tumor Stage and Folliculotropic Mycosis Fungoides.Foss F, Duvic M, Lerner A, Waksman J, Whittaker S. Clinical Efficacy of Romidepsin in Tumor Stage and Folliculotropic Mycosis Fungoides. Clinical Lymphoma, Myeloma & Leukemia 2016, 16: 637-643. PMID: 27637428, DOI: 10.1016/j.clml.2016.08.009.
  • The use of basiliximab-infliximab combination for the treatment of severe gastrointestinal acute GvHD.Nadeau M, Perreault S, Seropian S, Foss F, Isufi I, Cooper DL. The use of basiliximab-infliximab combination for the treatment of severe gastrointestinal acute GvHD. Bone Marrow Transplantation 2016, 51: 273-6. PMID: 26479982, DOI: 10.1038/bmt.2015.247.
  • A phase II study of cyclophosphamide, etoposide, vincristine and prednisone (CEOP) Alternating with Pralatrexate (P) as front line therapy for patients with peripheral T-cell lymphoma (PTCL): final results from the T- cell consortium trial.Advani RH, Ansell SM, Lechowicz MJ, Beaven AW, Loberiza F, Carson KR, Evens AM, Foss F, Horwitz S, Pro B, Pinter-Brown LC, Smith SM, Shustov AR, Savage KJ, M Vose J. A phase II study of cyclophosphamide, etoposide, vincristine and prednisone (CEOP) Alternating with Pralatrexate (P) as front line therapy for patients with peripheral T-cell lymphoma (PTCL): final results from the T- cell consortium trial. British Journal Of Haematology 2016, 172: 535-44. PMID: 26627450, PMCID: PMC5642048, DOI: 10.1111/bjh.13855.
  • CD4 + primary cutaneous small/medium-sized pleomorphic T-cell lymphoma: a retrospective case series and review of literature.James E, Sokhn JG, Gibson JF, Carlson K, Subtil A, Girardi M, Wilson LD, Foss F. CD4 + primary cutaneous small/medium-sized pleomorphic T-cell lymphoma: a retrospective case series and review of literature. Leukemia & Lymphoma 2015, 56: 951-7. PMID: 24996443, DOI: 10.3109/10428194.2014.938331.
  • Utility of ¹⁸fluoro-deoxyglucose positron emission tomography for prognosis and response assessments in a phase 2 study of romidepsin in patients with relapsed or refractory peripheral T-cell lymphoma.Horwitz S, Coiffier B, Foss F, Prince HM, Sokol L, Greenwood M, Caballero D, Morschhauser F, Pinter-Brown L, Iyer SP, Shustov A, Nichols J, Balser J, Balser B, Pro B. Utility of ¹⁸fluoro-deoxyglucose positron emission tomography for prognosis and response assessments in a phase 2 study of romidepsin in patients with relapsed or refractory peripheral T-cell lymphoma. Annals Of Oncology : Official Journal Of The European Society For Medical Oncology / ESMO 2015, 26: 774-9. PMID: 25605745, PMCID: PMC4374388, DOI: 10.1093/annonc/mdv010.
  • A Phase II trial of Belinostat (PXD101) in patients with relapsed or refractory peripheral or cutaneous T-cell lymphoma.Foss F, Advani R, Duvic M, Hymes KB, Intragumtornchai T, Lekhakula A, Shpilberg O, Lerner A, Belt RJ, Jacobsen ED, Laurent G, Ben-Yehuda D, Beylot-Barry M, Hillen U, Knoblauch P, Bhat G, Chawla S, Allen LF, Pohlman B. A Phase II trial of Belinostat (PXD101) in patients with relapsed or refractory peripheral or cutaneous T-cell lymphoma. British Journal Of Haematology 2015, 168: 811-9. PMID: 25404094, DOI: 10.1111/bjh.13222.
  • Belinostat in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma: Results of the Pivotal Phase II BELIEF (CLN-19) Study.O'Connor OA, Horwitz S, Masszi T, Van Hoof A, Brown P, Doorduijn J, Hess G, Jurczak W, Knoblauch P, Chawla S, Bhat G, Choi MR, Walewski J, Savage K, Foss F, Allen LF, Shustov A. Belinostat in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma: Results of the Pivotal Phase II BELIEF (CLN-19) Study. Journal Of Clinical Oncology : Official Journal Of The American Society Of Clinical Oncology 2015, 33: 2492-9. PMID: 26101246, PMCID: PMC5087312, DOI: 10.1200/JCO.2014.59.2782.
  • Cutaneous Lymphoma International Consortium Study of Outcome in Advanced Stages of Mycosis Fungoides and Sézary Syndrome: Effect of Specific Prognostic Markers on Survival and Development of a Prognostic Model.Scarisbrick JJ, Prince HM, Vermeer MH, Quaglino P, Horwitz S, Porcu P, Stadler R, Wood GS, Beylot-Barry M, Pham-Ledard A, Foss F, Girardi M, Bagot M, Michel L, Battistella M, Guitart J, Kuzel TM, Martinez-Escala ME, Estrach T, Papadavid E, Antoniou C, Rigopoulos D, Nikolaou V, Sugaya M, Miyagaki T, Gniadecki R, Sanches JA, Cury-Martins J, Miyashiro D, Servitje O, Muniesa C, Berti E, Onida F, Corti L, Hodak E, Amitay-Laish I, Ortiz-Romero PL, Rodríguez-Peralto JL, Knobler R, Porkert S, Bauer W, Pimpinelli N, Grandi V, Cowan R, Rook A, Kim E, Pileri A, Patrizi A, Pujol RM, Wong H, Tyler K, Stranzenbach R, Querfeld C, Fava P, Maule M, Willemze R, Evison F, Morris S, Twigger R, Talpur R, Kim J, Ognibene G, Li S, Tavallaee M, Hoppe RT, Duvic M, Whittaker SJ, Kim YH. Cutaneous Lymphoma International Consortium Study of Outcome in Advanced Stages of Mycosis Fungoides and Sézary Syndrome: Effect of Specific Prognostic Markers on Survival and Development of a Prognostic Model. Journal Of Clinical Oncology : Official Journal Of The American Society Of Clinical Oncology 2015, 33: 3766-73. PMID: 26438120, PMCID: PMC4979132, DOI: 10.1200/JCO.2015.61.7142.
  • Phase 1/2 study of mogamulizumab, a defucosylated anti-CCR4 antibody, in previously treated patients with cutaneous T-cell lymphoma.Duvic M, Pinter-Brown LC, Foss FM, Sokol L, Jorgensen JL, Challagundla P, Dwyer KM, Zhang X, Kurman MR, Ballerini R, Liu L, Kim YH. Phase 1/2 study of mogamulizumab, a defucosylated anti-CCR4 antibody, in previously treated patients with cutaneous T-cell lymphoma. Blood 2015, 125: 1883-9. PMID: 25605368, PMCID: PMC4375715, DOI: 10.1182/blood-2014-09-600924.
  • The Value and Relevance of the T Cell Lymphoma Registries and International Collaborations: the Case of COMPLETE and the T-Cell Project.Bellei M, Nabhan C, Pesce EA, Conte L, Vose JM, Foss F, Federico M. The Value and Relevance of the T Cell Lymphoma Registries and International Collaborations: the Case of COMPLETE and the T-Cell Project. Current Hematologic Malignancy Reports 2015, 10: 448-55. PMID: 26449717, DOI: 10.1007/s11899-015-0291-0.
  • Hematopoietic stem cell transplantation for primary cutaneous γδ T-cell lymphoma and refractory subcutaneous panniculitis-like T-cell lymphoma.Gibson JF, Alpdogan O, Subtil A, Girardi M, Wilson LD, Roberts K, Foss F. Hematopoietic stem cell transplantation for primary cutaneous γδ T-cell lymphoma and refractory subcutaneous panniculitis-like T-cell lymphoma. Journal Of The American Academy Of Dermatology 2015, 72: 1010-5.e5. PMID: 25981001, DOI: 10.1016/j.jaad.2015.01.003.
  • A fatal case of primary cutaneous gamma-delta T-cell lymphoma complicated by HLH and cardiac amyloidosis.Gibson JF, Kapur L, Sokhn J, Xu M, Foss FM. A fatal case of primary cutaneous gamma-delta T-cell lymphoma complicated by HLH and cardiac amyloidosis. Clinical Case Reports 2015, 3: 34-8. PMID: 25678971, PMCID: PMC4317209, DOI: 10.1002/ccr3.142.
  • Romidepsin for the Treatment of Peripheral T-Cell Lymphoma.Iyer SP, Foss FF. Romidepsin for the Treatment of Peripheral T-Cell Lymphoma. The Oncologist 2015, 20: 1084-91. PMID: 26099743, PMCID: PMC4571813, DOI: 10.1634/theoncologist.2015-0043.
  • Resimmune, an anti-CD3ε recombinant immunotoxin, induces durable remissions in patients with cutaneous T-cell lymphoma.Frankel AE, Woo JH, Ahn C, Foss FM, Duvic M, Neville PH, Neville DM. Resimmune, an anti-CD3ε recombinant immunotoxin, induces durable remissions in patients with cutaneous T-cell lymphoma. Haematologica 2015, 100: 794-800. PMID: 25795722, PMCID: PMC4450625, DOI: 10.3324/haematol.2015.123711.
  • Genomic landscape of cutaneous T cell lymphoma.Choi J, Goh G, Walradt T, Hong BS, Bunick CG, Chen K, Bjornson RD, Maman Y, Wang T, Tordoff J, Carlson K, Overton JD, Liu KJ, Lewis JM, Devine L, Barbarotta L, Foss FM, Subtil A, Vonderheid EC, Edelson RL, Schatz DG, Boggon TJ, Girardi M, Lifton RP. Genomic landscape of cutaneous T cell lymphoma. Nature Genetics 2015, 47: 1011-9. PMID: 26192916, PMCID: PMC4552614, DOI: 10.1038/ng.3356.
  • Pilot study of sorafenib in relapsed or refractory peripheral and cutaneous T-cell lymphoma.Gibson JF, Foss F, Cooper D, Seropian S, Irizarry D, Barbarotta L, Lansigan F. Pilot study of sorafenib in relapsed or refractory peripheral and cutaneous T-cell lymphoma. British Journal Of Haematology 2014, 167: 141-4. PMID: 24888971, DOI: 10.1111/bjh.12944.
  • Romidepsin for the treatment of relapsed/refractory peripheral T-cell lymphoma: pivotal study update demonstrates durable responses.Coiffier B, Pro B, Prince HM, Foss F, Sokol L, Greenwood M, Caballero D, Morschhauser F, Wilhelm M, Pinter-Brown L, Padmanabhan Iyer S, Shustov A, Nielsen T, Nichols J, Wolfson J, Balser B, Horwitz S. Romidepsin for the treatment of relapsed/refractory peripheral T-cell lymphoma: pivotal study update demonstrates durable responses. Journal Of Hematology & Oncology 2014, 7: 11. PMID: 24456586, PMCID: PMC4016573, DOI: 10.1186/1756-8722-7-11.
  • Tolerability to romidepsin in patients with relapsed/refractory T-cell lymphoma.Foss F, Coiffier B, Horwitz S, Pro B, Prince HM, Sokol L, Greenwood M, Lerner A, Caballero D, Baran E, Kim E, Nichols J, Balser B, Wolfson J, Whittaker S. Tolerability to romidepsin in patients with relapsed/refractory T-cell lymphoma. Biomarker Research 2014, 2: 16. PMID: 25279222, PMCID: PMC4181623, DOI: 10.1186/2050-7771-2-16.
  • Treatment strategies for peripheral T-cell lymphomas.Foss FM. Treatment strategies for peripheral T-cell lymphomas. Best Practice & Research. Clinical Haematology 2013, 26: 43-56. PMID: 23768640, DOI: 10.1016/j.beha.2013.04.005.
  • Polymorphisms in DNA repair pathway genes, body mass index, and risk of non-Hodgkin lymphoma.Chen Y, Zheng T, Lan Q, Kim C, Qin Q, Foss F, Chen X, Holford T, Leaderer B, Boyle P, Wang C, Dai M, Liu Z, Ma S, Chanock SJ, Rothman N, Zhang Y. Polymorphisms in DNA repair pathway genes, body mass index, and risk of non-Hodgkin lymphoma. American Journal Of Hematology 2013, 88: 606-11. PMID: 23619945, PMCID: PMC3902049, DOI: 10.1002/ajh.23463.
  • Acute toxicity and risk of infection during total skin electron beam therapy for mycosis fungoides.Lloyd S, Chen Z, Foss FM, Girardi M, Wilson LD. Acute toxicity and risk of infection during total skin electron beam therapy for mycosis fungoides. Journal Of The American Academy Of Dermatology 2013, 69: 537-43. PMID: 23849563, DOI: 10.1016/j.jaad.2013.04.063.
  • A multicenter phase II trial to determine the safety and efficacy of combination therapy with denileukin diftitox and cyclophosphamide, doxorubicin, vincristine and prednisone in untreated peripheral T-cell lymphoma: the CONCEPT study.Foss FM, Sjak-Shie N, Goy A, Jacobsen E, Advani R, Smith MR, Komrokji R, Pendergrass K, Bolejack V. A multicenter phase II trial to determine the safety and efficacy of combination therapy with denileukin diftitox and cyclophosphamide, doxorubicin, vincristine and prednisone in untreated peripheral T-cell lymphoma: the CONCEPT study. Leukemia & Lymphoma 2013, 54: 1373-9. PMID: 23278639, DOI: 10.3109/10428194.2012.742521.
  • Pralatrexate: treatment of T-cell non-Hodgkin's lymphoma.Parker T, Barbarotta L, Foss F. Pralatrexate: treatment of T-cell non-Hodgkin's lymphoma. Future Oncology (London, England) 2013, 9: 21-9. PMID: 23252560, DOI: 10.2217/fon.12.168.
  • Polymorphisms in immune function genes and non-Hodgkin lymphoma survival.Aschebrook-Kilfoy B, Zheng T, Foss F, Ma S, Han X, Lan Q, Holford T, Chen Y, Leaderer B, Rothman N, Zhang Y. Polymorphisms in immune function genes and non-Hodgkin lymphoma survival. Journal Of Cancer Survivorship : Research And Practice 2012, 6: 102-14. PMID: 22113576, PMCID: PMC3326600, DOI: 10.1007/s11764-010-0164-4.
  • Identification of an active, well-tolerated dose of pralatrexate in patients with relapsed or refractory cutaneous T-cell lymphoma.Horwitz SM, Kim YH, Foss F, Zain JM, Myskowski PL, Lechowicz MJ, Fisher DC, Shustov AR, Bartlett NL, Delioukina ML, Koutsoukos T, Saunders ME, O'Connor OA, Duvic M. Identification of an active, well-tolerated dose of pralatrexate in patients with relapsed or refractory cutaneous T-cell lymphoma. Blood 2012, 119: 4115-22. PMID: 22394596, DOI: 10.1182/blood-2011-11-390211.
  • Long-term follow-up and survival of cutaneous T-cell lymphoma patients treated with extracorporeal photopheresis.Knobler R, Duvic M, Querfeld C, Straus D, Horwitz S, Zain J, Foss F, Kuzel T, Campbell K, Geskin L. Long-term follow-up and survival of cutaneous T-cell lymphoma patients treated with extracorporeal photopheresis. Photodermatology, Photoimmunology & Photomedicine 2012, 28: 250-7. PMID: 22971190, DOI: 10.1111/j.1600-0781.2012.00689.x.
  • Genetic polymorphisms in IL10RA and TNF modify the association between blood transfusion and risk of non-Hodgkin lymphoma.Bi X, Zheng T, Lan Q, Xu Z, Chen Y, Zhu G, Foss F, Kim C, Dai M, Zhao P, Holford T, Leaderer B, Boyle P, Deng Q, Chanock SJ, Rothman N, Zhang Y. Genetic polymorphisms in IL10RA and TNF modify the association between blood transfusion and risk of non-Hodgkin lymphoma. American Journal Of Hematology 2012, 87: 766-9. PMID: 22649007, PMCID: PMC3576861, DOI: 10.1002/ajh.23244.
  • Results from a pivotal, open-label, phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapy.Coiffier B, Pro B, Prince HM, Foss F, Sokol L, Greenwood M, Caballero D, Borchmann P, Morschhauser F, Wilhelm M, Pinter-Brown L, Padmanabhan S, Shustov A, Nichols J, Carroll S, Balser J, Balser B, Horwitz S. Results from a pivotal, open-label, phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapy. Journal Of Clinical Oncology : Official Journal Of The American Society Of Clinical Oncology 2012, 30: 631-6. PMID: 22271479, DOI: 10.1200/JCO.2011.37.4223.
  • Genetic polymorphisms in oxidative stress pathway genes and modification of BMI and risk of non-Hodgkin lymphoma.Kim C, Zheng T, Lan Q, Chen Y, Foss F, Chen X, Holford T, Leaderer B, Boyle P, Chanock SJ, Rothman N, Zhang Y. Genetic polymorphisms in oxidative stress pathway genes and modification of BMI and risk of non-Hodgkin lymphoma. Cancer Epidemiology, Biomarkers & Prevention : A Publication Of The American Association For Cancer Research, Cosponsored By The American Society Of Preventive Oncology 2012, 21: 866-8. PMID: 22374993, PMCID: PMC3394153, DOI: 10.1158/1055-9965.EPI-12-0010.
  • Pralatrexate is an effective treatment for relapsed or refractory transformed mycosis fungoides: a subgroup efficacy analysis from the PROPEL study.Foss F, Horwitz SM, Coiffier B, Bartlett N, Popplewell L, Pro B, Pinter-Brown LC, Shustov A, Furman RR, Haioun C, Koutsoukos T, O'Connor OA. Pralatrexate is an effective treatment for relapsed or refractory transformed mycosis fungoides: a subgroup efficacy analysis from the PROPEL study. Clinical Lymphoma, Myeloma & Leukemia 2012, 12: 238-43. PMID: 22542448, DOI: 10.1016/j.clml.2012.01.010.
  • T-cell lymphomas in South america and europe.Bellei M, Chiattone CS, Luminari S, Pesce EA, Cabrera ME, de Souza CA, Gabús R, Zoppegno L, Zoppegno L, Milone J, Pavlovsky A, Connors JM, Foss FM, Horwitz SM, Liang R, Montoto S, Pileri SA, Polliack A, Vose JM, Zinzani PL, Zucca E, Federico M. T-cell lymphomas in South america and europe. Revista Brasileira De Hematologia E Hemoterapia 2012, 34: 42-7. PMID: 23049383, PMCID: PMC3459617, DOI: 10.5581/1516-8484.20120013.
  • Late afternoon dosing of plerixafor for stem cell mobilization: a practical solution.Cooper DL, Pratt K, Baker J, Medoff E, Conkling-Walsh A, Foss F, Snyder E, Yen W, Seropian SE. Late afternoon dosing of plerixafor for stem cell mobilization: a practical solution. Clinical Lymphoma, Myeloma & Leukemia 2011, 11: 267-72. PMID: 21658654, DOI: 10.1016/j.clml.2011.03.014.
  • Cytokine polymorphisms in Th1/Th2 pathway genes, body mass index, and risk of non-Hodgkin lymphoma.Chen Y, Zheng T, Lan Q, Foss F, Kim C, Chen X, Dai M, Li Y, Holford T, Leaderer B, Boyle P, Chanock SJ, Rothman N, Zhang Y. Cytokine polymorphisms in Th1/Th2 pathway genes, body mass index, and risk of non-Hodgkin lymphoma. Blood 2011, 117: 585-90. PMID: 20952689, PMCID: PMC3031482, DOI: 10.1182/blood-2010-07-295097.
  • Evolving Therapy of Peripheral T-cell Lymphoma: 2010 and beyond.Foss F. Evolving Therapy of Peripheral T-cell Lymphoma: 2010 and beyond. Therapeutic Advances In Hematology 2011, 2: 161-73. PMID: 23556087, PMCID: PMC3573405, DOI: 10.1177/2040620711408491.
  • Predictors of complete responses with denileukin diftitox in cutaneous T-cell lymphoma.Foss F, Duvic M, Olsen EA. Predictors of complete responses with denileukin diftitox in cutaneous T-cell lymphoma. American Journal Of Hematology 2011, 86: 627-30. PMID: 21674574, DOI: 10.1002/ajh.22039.
  • Molecular predictors of response in aggressive T-cell lymphomas.Foss FM. Molecular predictors of response in aggressive T-cell lymphomas. Cancer Journal (Sudbury, Mass.) 2011, 17: 142-8. PMID: 21427558, DOI: 10.1097/PPO.0b013e31821828b7.
  • Multicenter phase II trial of temozolomide in mycosis fungoides/sezary syndrome: correlation with O⁶-methylguanine-DNA methyltransferase and mismatch repair proteins.Querfeld C, Rosen ST, Guitart J, Rademaker A, Pezen DS, Dolan ME, Baron J, Yarosh DB, Foss F, Kuzel TM. Multicenter phase II trial of temozolomide in mycosis fungoides/sezary syndrome: correlation with O⁶-methylguanine-DNA methyltransferase and mismatch repair proteins. Clinical Cancer Research : An Official Journal Of The American Association For Cancer Research 2011, 17: 5748-54. PMID: 21747120, PMCID: PMC3725971, DOI: 10.1158/1078-0432.CCR-11-0556.
  • Evaluation of the pharmacokinetics, preclinical and clinical efficacy of pralatrexate for the treatment of T-cell lymphoma.Foss FM. Evaluation of the pharmacokinetics, preclinical and clinical efficacy of pralatrexate for the treatment of T-cell lymphoma. Expert Opinion On Drug Metabolism & Toxicology 2011, 7: 1141-52. PMID: 21726160, DOI: 10.1517/17425255.2011.595404.
  • Hematology: relapsed and refractory PTCL--into the therapeutic abyss.Foss F. Hematology: relapsed and refractory PTCL--into the therapeutic abyss. Nature Reviews. Clinical Oncology 2011, 8: 321-2. PMID: 21468128, DOI: 10.1038/nrclinonc.2011.51.
  • Peripheral T-cell lymphoma.Foss FM, Zinzani PL, Vose JM, Gascoyne RD, Rosen ST, Tobinai K. Peripheral T-cell lymphoma. Blood 2011, 117: 6756-67. PMID: 21493798, DOI: 10.1182/blood-2010-05-231548.
  • Sézary syndrome: immunopathogenesis, literature review of therapeutic options, and recommendations for therapy by the United States Cutaneous Lymphoma Consortium (USCLC).Olsen EA, Rook AH, Zic J, Kim Y, Porcu P, Querfeld C, Wood G, Demierre MF, Pittelkow M, Wilson LD, Pinter-Brown L, Advani R, Parker S, Kim EJ, Junkins-Hopkins JM, Foss F, Cacchio P, Duvic M. Sézary syndrome: immunopathogenesis, literature review of therapeutic options, and recommendations for therapy by the United States Cutaneous Lymphoma Consortium (USCLC). Journal Of The American Academy Of Dermatology 2011, 64: 352-404. PMID: 21145619, DOI: 10.1016/j.jaad.2010.08.037.
  • Vegetable and fruit intake and non-Hodgkin lymphoma survival in Connecticut women.Han X, Zheng T, Foss F, Holford TR, Ma S, Zhao P, Dai M, Kim C, Zhang Y, Bai Y, Zhang Y. Vegetable and fruit intake and non-Hodgkin lymphoma survival in Connecticut women. Leukemia & Lymphoma 2010, 51: 1047-54. PMID: 20350273, PMCID: PMC3110752, DOI: 10.3109/10428191003690364.
  • Alcohol consumption and non-Hodgkin lymphoma survival.Han X, Zheng T, Foss FM, Ma S, Holford TR, Boyle P, Leaderer B, Zhao P, Dai M, Zhang Y. Alcohol consumption and non-Hodgkin lymphoma survival. Journal Of Cancer Survivorship : Research And Practice 2010, 4: 101-9. PMID: 20039144, PMCID: PMC3141078, DOI: 10.1007/s11764-009-0111-4.
  • Genetic polymorphisms in the metabolic pathway and non-Hodgkin lymphoma survival.Han X, Zheng T, Foss FM, Lan Q, Holford TR, Rothman N, Ma S, Zhang Y. Genetic polymorphisms in the metabolic pathway and non-Hodgkin lymphoma survival. American Journal Of Hematology 2010, 85: 51-6. PMID: 20029944, PMCID: PMC2964927, DOI: 10.1002/ajh.21580.
  • Rapid generation of maturationally synchronized human dendritic cells: contribution to the clinical efficacy of extracorporeal photochemotherapy.Berger C, Hoffmann K, Vasquez JG, Mane S, Lewis J, Filler R, Lin A, Zhao H, Durazzo T, Baird A, Lin W, Foss F, Christensen I, Girardi M, Tigelaar R, Edelson R. Rapid generation of maturationally synchronized human dendritic cells: contribution to the clinical efficacy of extracorporeal photochemotherapy. Blood 2010, 116: 4838-47. PMID: 20720185, PMCID: PMC3321745, DOI: 10.1182/blood-2009-11-256040.
  • Role of denileukin diftitox in the treatment of persistent or recurrent cutaneous T-cell lymphoma.Lansigan F, Stearns DM, Foss F. Role of denileukin diftitox in the treatment of persistent or recurrent cutaneous T-cell lymphoma. Cancer Management And Research 2010, 2: 53-9. PMID: 21188096, PMCID: PMC3004568, DOI: 10.2147/cmar.s5009.
  • Current and emerging treatment strategies for cutaneous T-cell lymphoma.Lansigan F, Foss FM. Current and emerging treatment strategies for cutaneous T-cell lymphoma. Drugs 2010, 70: 273-86. PMID: 20166766, DOI: 10.2165/11532190-000000000-00000.
  • Clinical roundtable monograph. T-cell lymphoma: therapeutic overview and disease state awareness.Armitage JO, Hsi ED, Foss FM. Clinical roundtable monograph. T-cell lymphoma: therapeutic overview and disease state awareness. Clinical Advances In Hematology & Oncology : H&O 2010, 8: 1-15. PMID: 21491667.
  • Enhancing existing approaches to peripheral T-cell lymphoma.Foss FM. Enhancing existing approaches to peripheral T-cell lymphoma. Seminars In Hematology 2010, 47 Suppl 1: S8-10. PMID: 20359584, DOI: 10.1053/j.seminhematol.2010.01.012.
  • Advances in the treatment of T-cell lymphomas.Foss F. Advances in the treatment of T-cell lymphomas. Clinical Advances In Hematology & Oncology : H&O 2009, 7: 1-14; quiz 15-6. PMID: 20068547.
  • Reduced-intensity and nonmyeloablative conditioning regimens.Foss F, van Besien K. Reduced-intensity and nonmyeloablative conditioning regimens. Cancer Treatment And Research 2009, 144: 209-32. PMID: 19779868, DOI: 10.1007/978-0-387-78580-6_9.
  • The importance of accurately characterizing lymphoproliferative disease.Foss FM. The importance of accurately characterizing lymphoproliferative disease. Oncology (Williston Park, N.Y.) 2009, 23: 1168, 1170. PMID: 20043467.
  • Cutaneous T-cell lymphoma.Lansigan F, Choi J, Foss FM. Cutaneous T-cell lymphoma. Hematology/oncology Clinics Of North America 2008, 22: 979-96, x. PMID: 18954747, DOI: 10.1016/j.hoc.2008.07.014.
  • Cutaneous T-cell lymphoma: Biologic targets for therapy.Choi J, Foss F. Cutaneous T-cell lymphoma: Biologic targets for therapy. Current Hematologic Malignancy Reports 2007, 2: 272-7. PMID: 20425380, DOI: 10.1007/s11899-007-0037-8.
  • Efficacy and tolerability of currently available therapies for the mycosis fungoides and Sezary syndrome variants of cutaneous T-cell lymphoma.Whittaker SJ, Foss FM. Efficacy and tolerability of currently available therapies for the mycosis fungoides and Sezary syndrome variants of cutaneous T-cell lymphoma. Cancer Treatment Reviews 2007, 33: 146-60. PMID: 17275192, DOI: 10.1016/j.ctrv.2006.08.006.
  • Efficacy of denileukin diftitox in subcutaneous panniculitis-like T-cell lymphoma.Hathaway T, Subtil A, Kuo P, Foss F. Efficacy of denileukin diftitox in subcutaneous panniculitis-like T-cell lymphoma. Clinical Lymphoma & Myeloma 2007, 7: 541-5. PMID: 18021473, DOI: 10.3816/clm.2007.n.040.
  • Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma.Olsen EA, Kim YH, Kuzel TM, Pacheco TR, Foss FM, Parker S, Frankel SR, Chen C, Ricker JL, Arduino JM, Duvic M. Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma. Journal Of Clinical Oncology : Official Journal Of The American Society Of Clinical Oncology 2007, 25: 3109-15. PMID: 17577020, DOI: 10.1200/JCO.2006.10.2434.
  • Mycosis fungoides: pathophysiology and emerging therapies.Duvic M, Foss FM. Mycosis fungoides: pathophysiology and emerging therapies. Seminars In Oncology 2007, 34: S21-8. PMID: 18086343, DOI: 10.1053/j.seminoncol.2007.11.006.
  • Efficacy of low dose clofarabine in refractory precursor T- acute lymphoblastic leukemia.Choi J, Foss F. Efficacy of low dose clofarabine in refractory precursor T- acute lymphoblastic leukemia. The Yale Journal Of Biology And Medicine 2006, 79: 169-72. PMID: 17940627, PMCID: PMC1994805.
  • A phase II open-label study of recombinant human interleukin-12 in patients with stage IA, IB, or IIA mycosis fungoides.Duvic M, Sherman ML, Wood GS, Kuzel TM, Olsen E, Foss F, Laliberté RJ, Ryan JL, Zonno K, Rook AH. A phase II open-label study of recombinant human interleukin-12 in patients with stage IA, IB, or IIA mycosis fungoides. Journal Of The American Academy Of Dermatology 2006, 55: 807-13. PMID: 17052486, DOI: 10.1016/j.jaad.2006.06.038.
  • CTCL: the most common type of primary cutaneous lymphoma: introduction.Foss F, Whittaker S. CTCL: the most common type of primary cutaneous lymphoma: introduction. Seminars In Oncology 2006, 33: S1-2. PMID: 16516667, DOI: 10.1053/j.seminoncol.2005.12.014.
  • Clinical experience: practical management of five patients with cutaneous T-cell lymphoma (CTCL)-related symptoms.Dummer R, Foss F, Dreno B, Bagot M. Clinical experience: practical management of five patients with cutaneous T-cell lymphoma (CTCL)-related symptoms. Seminars In Oncology 2006, 33: S26-32. PMID: 16516673, DOI: 10.1053/j.seminoncol.2005.12.020.
  • Clinical experience with denileukin diftitox (ONTAK).Foss F. Clinical experience with denileukin diftitox (ONTAK). Seminars In Oncology 2006, 33: S11-6. PMID: 16516670, DOI: 10.1053/j.seminoncol.2005.12.017.
  • Biologic correlates of response and survival in patients with cutaneous T-cell lymphoma treated with denileukin diftitox.Chin KM, Foss FM. Biologic correlates of response and survival in patients with cutaneous T-cell lymphoma treated with denileukin diftitox. Clinical Lymphoma & Myeloma 2006, 7: 199-204. PMID: 17229335, DOI: 10.3816/CLM.2006.n.059.
  • Immunomodulatory effects of rexinoids.Foss F. Immunomodulatory effects of rexinoids. Seminars In Oncology 2006, 33: S21-5. PMID: 16516672, DOI: 10.1053/j.seminoncol.2005.12.019.
  • The role of purine analogues in low-intensity regimens with allogeneic hematopoietic stem cell transplantation.Foss FM. The role of purine analogues in low-intensity regimens with allogeneic hematopoietic stem cell transplantation. Seminars In Hematology 2006, 43: S35-43. PMID: 16549113, DOI: 10.1053/j.seminhematol.2005.12.007.
  • A phase-1 trial of bexarotene and denileukin diftitox in patients with relapsed or refractory cutaneous T-cell lymphoma.Foss F, Demierre MF, DiVenuti G. A phase-1 trial of bexarotene and denileukin diftitox in patients with relapsed or refractory cutaneous T-cell lymphoma. Blood 2005, 106: 454-7. PMID: 15811959, DOI: 10.1182/blood-2004-11-4570.
  • Activity of gallium nitrate in refractory peripheral T-cell lymphoma.Huang Z, Higgins B, Foss F. Activity of gallium nitrate in refractory peripheral T-cell lymphoma. Clinical Lymphoma 2005, 6: 43-5. PMID: 15989706, DOI: 10.3816/clm.2005.n.026.
  • Prospective study of extracorporeal photopheresis in steroid-refractory or steroid-resistant extensive chronic graft-versus-host disease: analysis of response and survival incorporating prognostic factors.Foss FM, DiVenuti GM, Chin K, Sprague K, Grodman H, Klein A, Chan G, Stiffler K, Miller KB. Prospective study of extracorporeal photopheresis in steroid-refractory or steroid-resistant extensive chronic graft-versus-host disease: analysis of response and survival incorporating prognostic factors. Bone Marrow Transplantation 2005, 35: 1187-93. PMID: 15852025, DOI: 10.1038/sj.bmt.1704984.
  • Nucleoside analogs and antimetabolite therapies for myelodysplastic syndrome.Foss FM. Nucleoside analogs and antimetabolite therapies for myelodysplastic syndrome. Best Practice & Research. Clinical Haematology 2004, 17: 573-84. PMID: 15494295, DOI: 10.1016/j.beha.2004.08.009.
  • Mycosis fungoides and the Sézary syndrome.Foss F. Mycosis fungoides and the Sézary syndrome. Current Opinion In Oncology 2004, 16: 421-8. PMID: 15314509, DOI: 10.1097/00001622-200409000-00002.
  • Persistence of host dendritic cells after transplantation is associated with graft-versus-host disease.Chan GW, Gorgun G, Miller KB, Foss FM. Persistence of host dendritic cells after transplantation is associated with graft-versus-host disease. Biology Of Blood And Marrow Transplantation : Journal Of The American Society For Blood And Marrow Transplantation 2003, 9: 170-6. PMID: 12652467, DOI: 10.1053/bbmt.2003.50006.
  • Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 10-2003. A 72-year-old man with rapidly progressive leukemia, rash, and multiorgan failure.Foss FM, Aquino SL, Ferry JA. Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 10-2003. A 72-year-old man with rapidly progressive leukemia, rash, and multiorgan failure. The New England Journal Of Medicine 2003, 348: 1267-75. PMID: 12660391, DOI: 10.1056/NEJMcpc030003.
  • Extracorporeal photopheresis in the treatment of graft-vs-host disease.Foss FM. Extracorporeal photopheresis in the treatment of graft-vs-host disease. Journal Of Cutaneous Medicine And Surgery 2003, 7: 13-7. PMID: 12958702, DOI: 10.1007/s10227-003-5003-z.
  • Overview of cutaneous T-cell lymphoma: prognostic factors and novel therapeutic approaches.Foss F. Overview of cutaneous T-cell lymphoma: prognostic factors and novel therapeutic approaches. Leukemia & Lymphoma 2003, 44 Suppl 3: S55-61. PMID: 15202526, DOI: 10.1080/10428190310001623757.
  • Interleukin-2 receptor-directed therapies for cutaneous lymphomas.Foss FM, Waldmann TA. Interleukin-2 receptor-directed therapies for cutaneous lymphomas. Hematology/oncology Clinics Of North America 2003, 17: 1449-58. PMID: 14710895, DOI: 10.1016/s0889-8588(03)00110-2.
  • Novel agents for cutaneous T-cell lymphoma.Kuzel TM, Junghans R, Foss FM. Novel agents for cutaneous T-cell lymphoma. Hematology/oncology Clinics Of North America 2003, 17: 1459-66, x. PMID: 14710896, DOI: 10.1016/s0889-8588(03)00112-6.
  • Denileukin diftitox and hyper-CVAD in the treatment of human T-cell lymphotropic virus 1-associated acute T-cell leukemia/lymphoma.Di Venuti G, Nawgiri R, Foss F. Denileukin diftitox and hyper-CVAD in the treatment of human T-cell lymphotropic virus 1-associated acute T-cell leukemia/lymphoma. Clinical Lymphoma 2003, 4: 176-8. PMID: 14715100, DOI: 10.3816/clm.2003.n.027.
  • Reduced-intensity transplantation for patients with myelodysplastic syndrome achieves durable remission with less graft-versus-host disease.Chan GW, Foss FM, Klein AK, Sprague K, Miller KB. Reduced-intensity transplantation for patients with myelodysplastic syndrome achieves durable remission with less graft-versus-host disease. Biology Of Blood And Marrow Transplantation : Journal Of The American Society For Blood And Marrow Transplantation 2003, 9: 753-9. PMID: 14677114, DOI: 10.1016/j.bbmt.2003.08.002.
  • Peripheral T-cell lymphomas: diagnosis and management.Dearden CE, Foss FM. Peripheral T-cell lymphomas: diagnosis and management. Hematology/oncology Clinics Of North America 2003, 17: 1351-66. PMID: 14710889, DOI: 10.1016/s0889-8588(03)00119-9.
  • Quality-of-life improvements in cutaneous T-cell lymphoma patients treated with denileukin diftitox (ONTAK).Duvic M, Kuzel TM, Olsen EA, Martin AG, Foss FM, Kim YH, Heald PW, Bacha P, Nichols J, Liepa A. Quality-of-life improvements in cutaneous T-cell lymphoma patients treated with denileukin diftitox (ONTAK). Clinical Lymphoma 2002, 2: 222-8. PMID: 11970761, DOI: 10.3816/clm.2002.n.003.
  • Interleukin-7 receptor expression and activation in nonhaematopoietic neoplastic cell lines.Cosenza L, Gorgun G, Urbano A, Foss F. Interleukin-7 receptor expression and activation in nonhaematopoietic neoplastic cell lines. Cellular Signalling 2002, 14: 317-25. PMID: 11858939, DOI: 10.1016/s0898-6568(01)00245-5.
  • Altered biological activity associated with C-terminal modifications of IL-7.Görgün G, van der Spek J, Cosenza L, Menevse A, Foss F. Altered biological activity associated with C-terminal modifications of IL-7. Cytokine 2002, 20: 17-22. PMID: 12441142, DOI: 10.1006/cyto.2002.1974.
  • Arginine butyrate increases the cytotoxicity of DAB(389)IL-2 in leukemia and lymphoma cells by upregulation of IL-2Rbeta gene.Shao RH, Tian X, Gorgun G, Urbano AG, Foss FM. Arginine butyrate increases the cytotoxicity of DAB(389)IL-2 in leukemia and lymphoma cells by upregulation of IL-2Rbeta gene. Leukemia Research 2002, 26: 1077-83. PMID: 12443879, DOI: 10.1016/s0145-2126(02)00059-0.
  • Immunologic mechanisms of extracorporeal photochemotherapy in chronic graft-versus-host disease.Gorgun G, Miller KB, Foss FM. Immunologic mechanisms of extracorporeal photochemotherapy in chronic graft-versus-host disease. Blood 2002, 100: 941-7. PMID: 12130506, DOI: 10.1182/blood-2002-01-0068.
  • Immunomodulatory effects of RXR rexinoids: modulation of high-affinity IL-2R expression enhances susceptibility to denileukin diftitox.Gorgun G, Foss F. Immunomodulatory effects of RXR rexinoids: modulation of high-affinity IL-2R expression enhances susceptibility to denileukin diftitox. Blood 2002, 100: 1399-403. PMID: 12149223, DOI: 10.1182/blood-2002-01-0300.
  • Transformation in mycosis fungoides: the role of methotrexate.Abd-el-Baki J, Demierre MF, Li N, Foss FM. Transformation in mycosis fungoides: the role of methotrexate. Journal Of Cutaneous Medicine And Surgery 2002, 6: 109-16. PMID: 11992182, DOI: 10.1007/s10227-001-0040-y.
  • Mechanisms of apoptosis by the tyrphostin AG957 in hematopoietic cells.Urbano A, Gorgun G, Foss F. Mechanisms of apoptosis by the tyrphostin AG957 in hematopoietic cells. Biochemical Pharmacology 2002, 63: 689-92. PMID: 11992636, DOI: 10.1016/s0006-2952(01)00916-9.
  • Structure function analysis of interleukin 7: requirement for an aromatic ring at position 143 of helix D.vanderSpek JC, Sutherland JA, Gill BM, Gorgun G, Foss FM, Murphy JR. Structure function analysis of interleukin 7: requirement for an aromatic ring at position 143 of helix D. Cytokine 2002, 17: 227-33. PMID: 12027403, DOI: 10.1006/cyto.2002.1004.
  • A phase II trial of daily perillyl alcohol in patients with advanced ovarian cancer: Eastern Cooperative Oncology Group Study E2E96.Bailey HH, Levy D, Harris LS, Schink JC, Foss F, Beatty P, Wadler S. A phase II trial of daily perillyl alcohol in patients with advanced ovarian cancer: Eastern Cooperative Oncology Group Study E2E96. Gynecologic Oncology 2002, 85: 464-8. PMID: 12051875, DOI: 10.1006/gyno.2002.6647.
  • Immunologic mechanisms of antitumor activity.Foss FM. Immunologic mechanisms of antitumor activity. Seminars In Oncology 2002, 29: 5-11. PMID: 12068382, DOI: 10.1053/sonc.2002.33076.
  • Lymphoma of the skin.Connors JM, Hsi ED, Foss FM. Lymphoma of the skin. Hematology / The Education Program Of The American Society Of Hematology. American Society Of Hematology. Education Program 2002, 263-82. PMID: 12446427, DOI: 10.1182/asheducation-2002.1.263.
  • Diphtheria fusion protein therapy of chemoresistant malignancies.Frankel AE, Rossi P, Kuzel TM, Foss F. Diphtheria fusion protein therapy of chemoresistant malignancies. Current Cancer Drug Targets 2002, 2: 19-36. PMID: 12188918, DOI: 10.2174/1568009023333944.
  • Comparative outcomes for mature T-cell and NK/T-cell lymphomas in people with and without HIV and to AIDS-defining lymphomas.Koh MJ, Merrill MH, Koh MJ, Stuver R, Alonso CD, Foss FM, Mayor AM, Gill J, Epeldegui M, Cachay E, Thorne JE, Silverberg MJ, Horberg MA, Althoff KN, Nijhawan AE, McGinnis KA, Lee JS, Rabkin CS, Napravnik S, Li J, Castilho JL, Shen C, Jain S. Comparative outcomes for mature T-cell and NK/T-cell lymphomas in people with and without HIV and to AIDS-defining lymphomas. Blood Advances 2022, 6: 1420-1431. PMID: 35026839, PMCID: PMC8905704, DOI: 10.1182/bloodadvances.2021006208.
  • Outcomes of Allogeneic Hematopoietic Cell Transplantation in T Cell Prolymphocytic Leukemia: A Contemporary Analysis from the Center for International Blood and Marrow Transplant Research.Murthy HS, Ahn KW, Estrada-Merly N, Alkhateeb HB, Bal S, Kharfan-Dabaja MA, Dholaria B, Foss F, Gowda L, Jagadeesh D, Sauter C, Abid MB, Aljurf M, Awan FT, Bacher U, Badawy SM, Battiwalla M, Bredeson C, Cerny J, Chhabra S, Deol A, Diaz MA, Farhadfar N, Freytes C, Gajewski J, Gandhi MJ, Ganguly S, Grunwald MR, Halter J, Hashmi S, Hildebrandt GC, Inamoto Y, Jimenez-Jimenez AM, Kalaycio M, Kamble R, Krem MM, Lazarus HM, Lazaryan A, Maakaron J, Munshi PN, Munker R, Nazha A, Nishihori T, Oluwole OO, Ortí G, Pan DC, Patel SS, Pawarode A, Rizzieri D, Saba NS, Savani B, Seo S, Ustun C, van der Poel M, Verdonck LF, Wagner JL, Wirk B, Oran B, Nakamura R, Scott B, Saber W. Outcomes of Allogeneic Hematopoietic Cell Transplantation in T Cell Prolymphocytic Leukemia: A Contemporary Analysis from the Center for International Blood and Marrow Transplant Research. Transplantation And Cellular Therapy 2022, 28: 187.e1-187.e10. PMID: 35081472, PMCID: PMC8977261, DOI: 10.1016/j.jtct.2022.01.017.
  • Safety considerations with the current treatments for peripheral T-cell lymphoma.Sethi T, Montanari F, Foss F. Safety considerations with the current treatments for peripheral T-cell lymphoma. Expert Opinion On Drug Safety 2022, 21: 653-660. PMID: 35129014, DOI: 10.1080/14740338.2022.2036120.
  • T-Cell Lymphomas, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology.Horwitz SM, Ansell S, Ai WZ, Barnes J, Barta SK, Brammer J, Clemens MW, Dogan A, Foss F, Ghione P, Goodman AM, Guitart J, Halwani A, Haverkos BM, Hoppe RT, Jacobsen E, Jagadeesh D, Jones A, Kallam A, Kim YH, Kumar K, Mehta-Shah N, Olsen EA, Rajguru SA, Rozati S, Said J, Shaver A, Shea L, Shinohara MM, Sokol L, Torres-Cabala C, Wilcox R, Wu P, Zain J, Dwyer M, Sundar H. T-Cell Lymphomas, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology. Journal Of The National Comprehensive Cancer Network : JNCCN 2022, 20: 285-308. PMID: 35276674, DOI: 10.6004/jnccn.2022.0015.
  • Peripheral Blood Involvement at Staging in Patients With Aggressive Peripheral T-Cell Lymphoma.Avery J, Chandhok N, Rainey C, Torres R, Huntington S, Isufi I, Seropian S, Xu ML, Foss F. Peripheral Blood Involvement at Staging in Patients With Aggressive Peripheral T-Cell Lymphoma. Clinical Lymphoma, Myeloma & Leukemia 2022 PMID: 35568635, DOI: 10.1016/j.clml.2022.04.019.

Clinical Trials

ConditionsStudy Title
Leukemia, otherA Phase 2 Study of Donor-Derived Multi-Tumor-Associated Antigen Specific T Cells (MT-401) Administered to Patients With Acute Myeloid Leukemia (AML) Following Hematopoietic Stem Cell Transplantation
Non-Hodgkin's LymphomaA Randomized, Phase IIB, Multicenter, Trial of Oral Azacytidine Plus Romidepsin Versus Investigator's Choice in Patients With Relapse or Refractory Peripheral T-cell Lymphoma (PTCL)
Non-Hodgkin's LymphomaA Phase 1 Study of SEA-TGT (SGN-TGT) in Subjects With Advanced Malignancies
Non-Hodgkin's LymphomaA Phase 1/2 Study of Oral LOXO-305 in Patients With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) or Non-Hodgkin Lymphoma (NHL)
Non-Hodgkin's LymphomaA Phase 1, Open-Label, Multicenter, Dose Escalation and Cohort Expansion Study of the Safety and Efficacy of Anti-CD70 Allogeneic CRISPR-Cas9-Engineered T Cells (CTX130) in Subjects With Relapsed or Refractory T or B Cell Malignancies
Non-Hodgkin's LymphomaA Multi-center Single Arm Phase II Study to Evaluate the Safety and Efficacy of Genetically Engineered Autologous Cells Expressing Anti-CD20 and Anti-CD19 Specific Chimeric Antigen Receptor in Subjects With Relapsed and/or Refractory Diffuse Large B Cell Lymphoma
KidneyA Phase 1 Dose Escalation and Cohort Expansion Study of the Safety and Efficacy of Allogeneic CRISPR-Cas9-Engineered T Cells (CTX130) in Subjects With Advanced, Relapsed or Refractory Renal Cell Carcinoma With Clear Cell Differentiation
Phase IA Phase 1 Study of TJ011133 Administered Alone or in Combination With Pembrolizumab or Rituximab in Subjects With Relapsed/Refractory Advanced Solid Tumors and Lymphoma
Hodgkin's LymphomaA Phase III, Randomized Study of Nivolumab (Opdivo) Plus AVD or Brentuximab Vedotin (Adcetris) Plus AVD in Patients (Age >/= 12 Years) With Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma
Hodgkin's Lymphoma; Lymphoid Leukemia; Non-Hodgkin's LymphomaManaged Access Program (MAP) to Provide Access to CTL019, for ALL or DLBCL Patients With Out of Specification Leukapheresis Product and/or Manufactured Tisagenlecleucel Out of Specification for Commercial Release
Non-Hodgkin's LymphomaA Randomized Phase III Trial of Consolidation With Autologous Hematopoietic Cell Transplantation Followed by Maintenance Rituximab vs. Maintenance Rituximab Alone for Patients With Mantle Cell Lymphoma in Minimal Residual Disease-Negative First Complete Remission
Non-Hodgkin's LymphomaA Randomized Double-Blind Phase III Study of Ibrutinib During and Following Autologous Stem Cell Transplantation Versus Placebo in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma of the Activated B-Cell Subtype
Lymphoid Leukemia; Non-Hodgkin's Lymphoma; Phase IAn Open-Label, Multicenter, Phase I Trial Evaluating the Safety and Pharmacokinetics of Escalating Doses of BTCT4465A in Patients With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia
Edit Profile